Haw Par Corporation Limited (HAWPY)

USD 28.64

(0.0%)

Total Assets Summary of Haw Par Corporation Limited

  • Haw Par Corporation Limited's latest annual total assets in 2023 was 3.59 Billion SGD , down -1.56% from previous year.
  • Haw Par Corporation Limited's latest quarterly total assets in 2024 Q1 was 3.81 Billion SGD , up 6.21% from previous quarter.
  • Haw Par Corporation Limited reported annual total assets of 3.65 Billion SGD in 2022, up 11.16% from previous year.
  • Haw Par Corporation Limited reported annual total assets of 3.28 Billion SGD in 2021, up 11.34% from previous year.
  • Haw Par Corporation Limited reported quarterly total assets of 3.81 Billion SGD for 2024 Q2, down 0.0% from previous quarter.
  • Haw Par Corporation Limited reported quarterly total assets of 3.59 Billion SGD for 2023 Q3, up 2.56% from previous quarter.

Annual Total Assets Chart of Haw Par Corporation Limited (2023 - 2001)

Historical Annual Total Assets of Haw Par Corporation Limited (2023 - 2001)

Year Total Assets Total Assets Growth
2023 3.59 Billion SGD -1.56%
2022 3.65 Billion SGD 11.16%
2021 3.28 Billion SGD 11.34%
2020 2.94 Billion SGD -9.01%
2019 3.24 Billion SGD 6.96%
2018 3.03 Billion SGD -11.37%
2017 3.41 Billion SGD 29.7%
2016 2.63 Billion SGD -2.09%
2015 2.69 Billion SGD -9.48%
2014 2.97 Billion SGD 15.91%
2013 2.56 Billion SGD 8.24%
2012 2.37 Billion SGD 26.32%
2011 1.87 Billion SGD -8.12%
2010 2.04 Billion SGD 1.95%
2009 2 Billion SGD 42.19%
2008 1.4 Billion SGD -30.85%
2007 2.03 Billion SGD 7.21%
2006 1.9 Billion SGD 36.21%
2005 1.39 Billion SGD 117.45%
2004 641.71 Million SGD -8.26%
2003 699.49 Million SGD -8.46%
2002 764.18 Million SGD -6.61%
2001 818.3 Million SGD 0.0%

Peer Total Assets Comparison of Haw Par Corporation Limited

Name Total Assets Total Assets Difference
AstraZeneca PLC 100.97 Billion USD 96.442%
Bristol-Myers Squibb Company PFD CONV 2 95.15 Billion USD 96.224%
CSPC Pharmaceutical Group Limited 6.52 Billion USD 44.924%
Clarus Therapeutics Holdings, Inc. 51.7 Million USD -6848.979%
Novartis AG 99.94 Billion USD 96.405%
PT Kalbe Farma Tbk. 1.75 Billion USD -104.304%